|
Forest Gets Untitled Letter After Reps Tout Weight Loss Adverse Event as Potentially Beneficial
Forest Laboratories has been hit with an untitled letter after two of its sales reps implied that weight loss while using Daliresp tablets — listed as an adverse reaction — could be beneficial for overweight chronic obstructive pulmonary disease (COPD) patients.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives